Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(42.9%)
Phase 1
2(28.6%)
Phase 3
2(28.6%)
7Total
Phase 2(3)
Phase 1(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT04238793Phase 1Completed

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Role: lead

NCT05613569Active Not Recruiting

A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study

Role: lead

NCT03412864Unknown

A Post Marketing Surveillance Study of INVOSSA K Inj.

Role: lead

NCT02341391Phase 1Completed

Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

Role: lead

NCT03383471Phase 3Unknown

The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis

Role: lead

NCT02072070Phase 3Completed

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Role: lead

NCT01825811Phase 2Completed

Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis

Role: lead

NCT02341378Phase 2Completed

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Role: lead

NCT01671072Phase 2Completed

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Role: lead

All 9 trials loaded